- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Results
4
Companies which are potentially undervalued and in an acceptable financial position.
4 companies
Tecan Group
Market Cap: CHF 1.7b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 137.30
7D
-2.6%
1Y
-3.7%
Roche Holding
Market Cap: CHF 253.5b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 317.20
7D
-0.3%
1Y
24.5%
Novartis
Market Cap: CHF 221.5b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 116.10
7D
-3.5%
1Y
28.0%
Siegfried Holding
Market Cap: CHF 3.6b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 81.50
7D
-1.4%
1Y
-8.0%